Mustang Bio, Inc. (MBIO): Price and Financial Metrics


Mustang Bio, Inc. (MBIO): $1.09

0.02 (+1.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 450

in industry

MBIO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MBIO is 0 -- better than only 6.93% of US stocks.
  • MBIO's went public 2.59 years ago, making it older than merely 6.99% of listed US stocks we're tracking.
  • As for revenue growth, note that MBIO's revenue has grown -200% over the past 12 months; that beats the revenue growth of merely 0.12% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Mustang Bio Inc, a group of peers worth examining would be ABEO, CNAT, MGEN, CTMX, and UMRX.
  • MBIO's SEC filings can be seen here. And to visit Mustang Bio Inc's official web site, go to www.mustangbio.com.

MBIO Stock Price Chart Interactive Chart >

Price chart for MBIO

MBIO Price/Volume Stats

Current price $1.09 52-week high $4.89
Prev. close $1.07 52-week low $1.01
Day low $1.01 Volume 2,040,843
Day high $1.10 Avg. volume 1,014,416
50-day MA $1.76 Dividend yield N/A
200-day MA $2.61 Market Cap 101.84M

Mustang Bio, Inc. (MBIO) Company Bio


Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.


MBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

MBIO Latest Social Stream


Loading social stream, please wait...

View Full MBIO Social Stream

Latest MBIO News From Around the Web

Below are the latest news stories about Mustang Bio Inc that investors may wish to consider to help them evaluate MBIO as an investment opportunity.

FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder

The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's (NASDAQ: MBIO) Investigational New Drug (IND) application for MB-207 in patients with X-linked severe combined immunodeficiency (XSCID). The application was submitted to initiate a pivotal Phase 2 study to assess MB-207 (lentiviral gene therapy) in patients who have been previously treated with a hematopoietic stem cell transplantation, and for whom re-treatment is indicated. The FDA has

Yahoo | January 25, 2022

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a hold, pending Chemistry, Manufacturing and Controls (“CMC”) clearance, on the Company’s Investigational New Drug

Yahoo | January 24, 2022

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic l

Yahoo | January 7, 2022

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022. Details of the events are as follows:

Yahoo | January 5, 2022

HC Wainwright Reaffirms Buy Rating for Mustang Bio (NASDAQ:MBIO)

HC Wainwright reiterated their buy rating on shares of Mustang Bio (NASDAQ:MBIO) in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a $7.00 price target on the stock. Other analysts have also issued research reports about the stock. BTIG Research reiterated a buy rating and issued a $11.00 price [] The post HC Wainwright Reaffirms Buy Rating for Mustang Bio (NASDAQ:MBIO) appeared first on ETF Daily News .

ETF Daily News | December 20, 2021

Read More 'MBIO' Stories Here

MBIO Price Returns

1-mo -35.88%
3-mo -51.34%
6-mo -62.28%
1-year -74.17%
3-year -66.56%
5-year N/A
YTD -34.34%
2021 -56.14%
2020 -7.23%
2019 38.78%
2018 -75.48%
2017 N/A

Continue Researching MBIO

Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:

Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9975 seconds.